Study directory

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Back to overview
23847studies shown
Showing 13,201-13,212 of 23,847
Drug study icon
CompletedEUCTR 2009-011238-84

3 dose regimens of agomelatine (10, 25, 25-50 mg) for depression

This study is completed in Slovakia, in Bulgaria, and in Finland. It is testing 3 dose regimens of agomelatine (10, 25, 25-50 mg) for depression.

In Slovakia
DepressionOther
Countries
Slovakia, Bulgaria, Finland
Sponsor
Institut de Recherches Internationales Servier
Condition
Depression
Other study type icon
CompletedEUCTR 2014-001519-38

3 doses of S 47445 for depression

This study is completed in Germany, in Czechia, in Hungary, .... It is testing 3 doses of S 47445 for depression.

In Germany
DepressionOther
Countries
Germany, Czechia, Hungary, ...
Sponsor
Institut de Recherches Internationales Servier
Condition
Depression
Drug study icon
CompletedNCT00101634

Long Acting Anti-Psychotic for schizophrenia

This study is completed. It is testing Long Acting Anti-Psychotic for schizophrenia.

Location not clearly listed
SchizophreniaDrugA study involving a medication or substance.Over 18 Years
Countries
Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Condition
Schizophrenia
Drug study icon
CompletedNCT02137993

A-prexa Compared to Zyprexa for schizophrenia

This study is completed. It is testing A-prexa Compared to Zyprexa for schizophrenia.

Location not clearly listed
SchizophreniaDrugFrom 20 Years to 65 Years
Countries
Sponsor
HK inno.N Corporation
Condition
Schizophrenia
Drug study icon
CompletedNCT02970292

Pimavanserin for schizophrenia

This study is completed in the United States, in Canada, in Bulgaria, .... It is testing pimavanserin for schizophrenia.

Multiple locations, including Phoenix
SchizophreniaDrugFrom 18 Years to 55 Years
Countries
United States, Canada, Bulgaria, ...
Sponsor
ACADIA Pharmaceuticals Inc.
Condition
Schizophrenia
Drug study icon
CompletedEUCTR 2005-004881-17

Agomelatine (25 mg/day with potential adjustment at 50 mg/day) given orally compared to placebo, for Bipolarity

This study is completed in Austria, in the Netherlands, in Spain, .... It is testing agomelatine (25 mg/day with potential adjustment at 50 mg/day) given orally compared to placebo, for Bipolarity.

In Austria
Bipolarity, DepressionOther
Countries
Austria, Netherlands, Spain, ...
Sponsor
Institut de Recherches Internationales Servier [...] 1. Institut de Recherches Internationales Servier 2. Laboratorios Servier S.L. (For Spain only)
Condition
Bipolarity, Depression
Other study type icon
CompletedEUCTR 2012-003699-37

Agomelatine (25mg/day with blinded potential adjustment to 50mg/day) versus escitalopram (10mg/day with blinded potential adjustment to 20mg/day) given orally for Anxiety

This study is completed in Czechia, in Germany, in Hungary, .... It is testing agomelatine (25mg/day with blinded potential adjustment to 50mg/day) versus escitalopram (10mg/day with blinded potential adjustment to 20mg/day) given orally for Anxiety.

In Czech Republic
AnxietyOther
Countries
Czechia, Germany, Hungary, ...
Sponsor
Institut de Recherches Internationales Servier
Condition
Anxiety
Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.